CD19 and neoplasm: We next evaluated the anti-tumor cytotoxicity of CD19-KIRS2/Dap12-BB CAR-T cells compared with CAR-T cells engineered with a CD19-targeted 41BB-based second-generation CAR (termed CD19-BBζ CAR) in Nalm6 cell-derived xenograft tumors (Figure 3A).